Appreciation efficiency of standard and alternative antituberculosis preventive therapy in children from different tuberculosis infection sources Source: Eur Respir J 2006; 28: Suppl. 50, 28s Year: 2006
Predicting outcomes and drug resistance with standardised treatment of active tuberculosis Source: Eur Respir J 2010; 36: 870-877 Year: 2010
Comparison of compliance of two therapeutic regimens in treatment of latent tuberculosis infection in Belgrade children Source: Eur Respir J 2004; 24: Suppl. 48, 648s Year: 2004
Therapeutic drug monitoring to prevent acquired drug resistance of fluoroquinolones in the treatment of tuberculosis Source: Eur Respir J , 49 (4) 1700173; DOI: 10.1183/13993003.00173-2017 Year: 2017
Therapeutic drug monitoring to prevent acquired drug resistance of fluoroquinolones in the treatment of tuberculosis Source: Eur Respir J , 49 (4) 1700317; DOI: 10.1183/13993003.00317-2017 Year: 2017
Therapeutic drug monitoring practice in patients with active tuberculosis: assessment of opportunities Source: Eur Respir J, 57 (1) 2002349; 10.1183/13993003.02349-2020 Year: 2021
The impact of drug resistance on TB control and elimination Source: International Congress 2014 – New diagnostics and better treatments for multidrug and extensively drug-resistant tuberculosis (M/XDR-TB) Year: 2014
The impact and cost-effectiveness of strategies to detect drug-resistant tuberculosis Source: Eur Respir J 2012; 39: 626-634 Year: 2012
Impact of adverse drug reactions on treatment interruption in TB patients with and without HIV coinfection Source: ISSN=ISSN 1810-6838, ISBN=, page=190 Year: 2006
New drugs and drug regimens in the treatment of chronic and MDR-TB - what is on the horizon? Source: Annual Congress 2005 - Challenges in the management of pulmonary tuberculosis: a continuous clinical problem Year: 2005
The role of adherence in tuberculosis HIV-positive patients treated in ambulatory regimen Source: Eur Respir J 2003; 21: 785-788 Year: 2003
Impact of extensive drug resistance on treatment outcomes in non-HIV infected adults with MDR-TB Source: Annual Congress 2007 - Multidrug-resistant tuberculosis and the emerging threat of extensively drug-resistant tuberculosis Year: 2007
Experience in the use of Bedakville in the therapy of multidrug-resistant tuberculosis and HIV infection. Source: International Congress 2018 – Drug-resistant tuberculosis and the sequelae of pulmonary tuberculosis Year: 2018
Rational use of tuberculosis drugs to prevent the development of drug resistance Source: Annual Congress 2012 - MDR- and XDR-TB: epidemiological and public health overview Year: 2012
Dose optimisation of first-line tuberculosis drugs using therapeutic drug monitoring in saliva: feasible for rifampicin, not for isoniazid Source: Eur Respir J, 56 (4) 2000803; 10.1183/13993003.00803-2020 Year: 2020
Evaluation of patient adherence to tuberculosis treatment by measuring drug metabolites in urine Source: Eur Respir J 2004; 24: Suppl. 48, 649s Year: 2004
Using results of drug sensitivity of infection source in initial chemotherapy choice in TB children and teenagers Source: Eur Respir J 2006; 28: Suppl. 50, 12s Year: 2006
A Cuban successful history on antituberculosis treatment and drug resistance surveillance Source: Annual Congress 2007 - Specific problems in caring for multidrug-resistant tuberculosis and tuberculosis/HIV cases Year: 2007
Patient choice promotes adherence in preventive treatment for latent tuberculosis Source: Eur Respir J 2007; 30: 728-735 Year: 2007
Comparing cost-effectiveness of standardised tuberculosis treatments given varying drug resistance Source: Eur Respir J 2014; 43: 566-581 Year: 2013